John Isaacs comments on the findings from the FINCH 1 and FINCH 3 trials and discusses how filgotinib might fit into the rheumatoid arthritis treatment landscape (2:56).
14-06-2019 | Rheumatoid arthritis | EULAR 2019 | Article
John Isaacs comments on the findings from the FINCH 1 and FINCH 3 trials and discusses how filgotinib might fit into the rheumatoid arthritis treatment landscape (2:56).